The WSIB is seeking applications for a new funding competition. The WSIB Research and Grants Program will be awarding one successful application for a systematic review that specifically aims to evaluate: a) the current state of evidence on the therapeutic use of medical cannabis for the treatment of health conditions that can be work-related, as indicated below; b) evidence supporting the use of specific classes of medical cannabis (e.g., dried cannabis, cannabis edibles, cannabis extracts and/or cannabis topicals), including information on dose of delta-9-tetrahydrocannabinol (THC) and/or cannabidiol (CBD), as well as cannabigerol (CBG) and cannabinol (CBN) where available, for the treatment of conditions that can be work-related; and c) evidence of any risks, adverse events, or harms associated with the therapeutic use of medical cannabis for health conditions that can be work-related.
Outcomes from the systematic review may be considered by the WSIB to determine whether the scientific evidence meets the recommended standards for scheduling, policy development or to underpin adjudicative support in case-by-case decision-making.
The WSIB specifically requests that the systematic review examine and evaluate the scientific evidence from primary research studies published since 2016 (the end of the literature review period covered by the NASEM report) for the use of non-pharmaceutical medical cannabis for health conditions which are currently designated work-related conditions and potential work-related conditions, including assessment of:
• therapeutic benefit
• dose, route of administration, and duration of treatment, where available
• any risks, adverse events, or harms resulting from treatment
For more information, including Proposal Instructions and how to apply, please click here.